
Viela Bio, Inc. EBITDA 2011-2026 | VIE
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Viela Bio, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -151 M | -89.5 M | 94.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 94.4 M | -151 M | -48.9 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 3.56 | 2.01 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 0.79 | -0.79 % | $ 4.31 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-65 M | - | 10.36 % | $ 9.8 M | ||
|
argenx SE
ARGX
|
-349 M | $ 703.3 | 0.41 % | $ 25 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 231.03 | 2.23 % | $ 5 B | ||
|
ADC Therapeutics SA
ADCT
|
-262 M | $ 4.22 | 2.18 % | $ 105 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.61 | 0.28 % | $ 8.69 B | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 6.63 | -0.75 % | $ 182 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
-85.6 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
-81.2 M | $ 14.36 | 1.13 % | $ 210 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 90.54 | -0.71 % | $ 27.2 B | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 8.05 | 1.64 % | $ 1.31 B | ||
|
AVEO Pharmaceuticals
AVEO
|
-49.5 M | - | - | $ 521 M | ||
|
Atea Pharmaceuticals
AVIR
|
-180 M | $ 6.05 | -0.82 % | $ 493 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.64 | 3.94 % | $ 16.6 M | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
BioCardia
BCDA
|
-11.6 M | $ 1.27 | 0.79 % | $ 26.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.51 | 4.86 % | $ 385 M | ||
|
Athira Pharma
ATHA
|
-99.9 M | - | - | $ 269 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 3.58 | -0.56 % | $ 7.79 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | ||
|
Actinium Pharmaceuticals
ATNM
|
-41.9 M | $ 1.11 | - | $ 33.4 M |